Clinically, elevated sPD-L1 levels are significantly associated with poor overall survival (OS) and progression-free survival (PFS) in cancer patients, including those with lung, gastric, and colorectal cancer receiving immune checkpoint inhibitors [84–87], suggesting that sPD-L1 could be a useful predictive biomarker for immunotherapy response. This evidence concerns the gene SPDL1 and cancer.